Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials

Frontiers in Neurology

Syed I. Khalid¹  Christopher Dardis³  Shafeeq S. Ladha³  Ryan Kelly⁴  Leonel Ampie⁴ 

[1] Chicago Medical School, Chicago, IL, United States;Department of Neurological Surgery, University of Virginia School of Medicine, Charlottesville, VA, United States;Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, United States;Georgetown University School of Medicine, Washington, DC, United States;Surgical Neurology Branch, NINDS, National Institutes of Health, Bethesda, MD, United States;

关键词: amyotrophic lateral sclerosis;    immunotherapy;    microglial activation;    neuroinflammation;    SOD1;   

DOI  :  10.3389/fneur.2017.00486

来源: DOAJ

【 摘 要 】

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons. Though many molecular and genetic causes are thought to serve as predisposing or disease propagating factors, the underlying pathogenesis of the disease is not known. Recent discoveries have demonstrated the presence of inflammation propagating substrates in the central nervous system of patients afflicted with ALS. Over the past decade, this hypothesis has incited an effort to better understand the role of the immune system in ALS and has led to the trial of several potential immune-modulating therapies. Here, we briefly review advances in the role of such therapies. The clinical trials discussed here are currently ongoing or have been concluded at the time of writing.

【 授权许可】

Unknown